430 related articles for article (PubMed ID: 23096698)
1. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
[TBL] [Abstract][Full Text] [Related]
2. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution.
Napoli C; Sperandio N; Lawlor RT; Scarpa A; Molinari H; Assfalg M
J Proteome Res; 2012 Feb; 11(2):1274-83. PubMed ID: 22066465
[TBL] [Abstract][Full Text] [Related]
3. Urinary metabolomic signature of esophageal cancer and Barrett's esophagus.
Davis VW; Schiller DE; Eurich D; Sawyer MB
World J Surg Oncol; 2012 Dec; 10():271. PubMed ID: 23241138
[TBL] [Abstract][Full Text] [Related]
4. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
Sahni S; Pandya AR; Hadden WJ; Nahm CB; Maloney S; Cook V; Toft JA; Wilkinson-White L; Gill AJ; Samra JS; Dona A; Mittal A
Int J Cancer; 2021 Mar; 148(6):1508-1518. PubMed ID: 33128797
[TBL] [Abstract][Full Text] [Related]
5. Low- and high-grade bladder cancer determination via human serum-based metabolomics approach.
Bansal N; Gupta A; Mitash N; Shakya PS; Mandhani A; Mahdi AA; Sankhwar SN; Mandal SK
J Proteome Res; 2013 Dec; 12(12):5839-50. PubMed ID: 24219689
[TBL] [Abstract][Full Text] [Related]
6. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
Farshidfar F; Weljie AM; Kopciuk KA; Hilsden R; McGregor SE; Buie WD; MacLean A; Vogel HJ; Bathe OF
Br J Cancer; 2016 Sep; 115(7):848-57. PubMed ID: 27560555
[TBL] [Abstract][Full Text] [Related]
7. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
8. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
[TBL] [Abstract][Full Text] [Related]
9. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
[TBL] [Abstract][Full Text] [Related]
10. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS).
Chan EC; Koh PK; Mal M; Cheah PY; Eu KW; Backshall A; Cavill R; Nicholson JK; Keun HC
J Proteome Res; 2009 Jan; 8(1):352-61. PubMed ID: 19063642
[TBL] [Abstract][Full Text] [Related]
11. 1H HR-MAS NMR spectroscopy of tumor-induced local metabolic "field-effects" enables colorectal cancer staging and prognostication.
Jiménez B; Mirnezami R; Kinross J; Cloarec O; Keun HC; Holmes E; Goldin RD; Ziprin P; Darzi A; Nicholson JK
J Proteome Res; 2013 Feb; 12(2):959-68. PubMed ID: 23240862
[TBL] [Abstract][Full Text] [Related]
12. Exploratory investigation of plasma metabolomics in human lung adenocarcinoma.
Wen T; Gao L; Wen Z; Wu C; Tan CS; Toh WZ; Ong CN
Mol Biosyst; 2013 Sep; 9(9):2370-8. PubMed ID: 23857124
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
14. Low expression of IGFBP7 is associated with poor outcome of pancreatic ductal adenocarcinoma.
An W; Ben QW; Chen HT; Zheng JM; Huang L; Li GX; Li ZS
Ann Surg Oncol; 2012 Nov; 19(12):3971-8. PubMed ID: 22622471
[TBL] [Abstract][Full Text] [Related]
15. Metabonomic alterations from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma facilitate the identification of biomarkers in serum for early diagnosis of pancreatic cancer.
Lin X; Zhan B; Wen S; Li Z; Huang H; Feng J
Mol Biosyst; 2016 Aug; 12(9):2883-92. PubMed ID: 27400832
[TBL] [Abstract][Full Text] [Related]
16. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
[TBL] [Abstract][Full Text] [Related]
17. Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis.
Nahon P; Amathieu R; Triba MN; Bouchemal N; Nault JC; Ziol M; Seror O; Dhonneur G; Trinchet JC; Beaugrand M; Le Moyec L
Clin Cancer Res; 2012 Dec; 18(24):6714-22. PubMed ID: 23136190
[TBL] [Abstract][Full Text] [Related]
18. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system.
Rochefort MM; Ankeny JS; Kadera BE; Donald GW; Isacoff W; Wainberg ZA; Hines OJ; Donahue TR; Reber HA; Tomlinson JS
Ann Surg Oncol; 2013 Dec; 20(13):4322-9. PubMed ID: 23943022
[TBL] [Abstract][Full Text] [Related]
19. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
